Autoimmune Treatment Market (2009 - 2014)

Report Description

Autoimmune disorders result from an overactive immune response of a body working against its own cells. Almost all autoimmune diseases are chronic and have no permanent cure. Over 300 million patients across the globe suffer from these disorders. There are around 80 autoimmune diseases; and the cause of these remains unknown. Women constitute around 70%-75% of all autoimmune patients.

This report analyzes and categorizes the overall market for autoimmune disorders into the submarkets for applications, products, services, and technology. The applications market is further classified into segments catering to systemic autoimmune diseases (that affect several organs of the body) and localized autoimmune diseases (that affect only one organ in the body). The applications market is dominated by the treatment market for rheumatoid arthritis (RA) under systemic disease segment; and by multiple sclerosis (MS) under the localized disease segment. These two diseases account for 75% of the total applications market.

The product market is classified on the basis of autoimmune drugs, diagnostic equipment, and therapeutic and monitoring equipment. Drugs constitute the largest segment of the overall autoimmune products market. Some of the major generic drugs are NSAID, DMARD, biologic DMARD and 5-ASA; some major branded drugs are Avonex, Rebif, Copaxone, and Betaseron. The drugs market, as well as the therapy and monitoring market, is growing due to the chronic nature and the wide prevalence of autoimmune diseases.

Therapy and monitoring form the largest segment of the services market. The technologies used in the treatment of rheumatoid arthritis have a much larger share in comparison to other technologies used for the treatment of psoriasis. Pharmaceutical companies are now focusing on the treatment of autoimmune diseases as these have no permanent cure. A number of government associations and non-profit organizations across the globe are also funding the R&D activities for new drugs and therapies to treat autoimmune diseases. The report provides an in-depth analysis of the applications as well as the products and services market in four geographic regions, namely North America, Europe, Asia-Pacific, and Rest of the World (ROW).

Scope of the report

• Applications market for autoimmune disorders

  Rheumatoid arthritis, psoriasis, lupus, multiple sclerosis, inflammatory bowel diseases, type I diabetes, thyroid amongst other diseases.

• Services market for autoimmune disorders

  Consultation and diagnosis, therapy and monitoring, drug development, and other services (such as pharmacokinetic services – what a body does to a drug).

• Products market for autoimmune disorders

  Drugs, therapeutic and diagnostic equipment, and other products (such as bioinformatics).

What makes our reports unique?

1. We provide the longest market segmentation chain in the industry with our three-level market breakdown and our analysis of minimum 40 collectively exhaustive and mutually exclusive micro markets.
2. We provide 10% customization to ensure that our clients find the specific market intelligence they need.
3. Each report is about 150 pages, featuring 30+ market data tables, 30+ company profiles, and an analysis of 200 patents.
4. No single report by any other publisher provides market data for all market segments (i.e. products, services, applications, ingredients, and technology) covering the four geographies of North America, Europe, Asia Pacific, and ROW.
5. 15 pages of high level analysis identifying opportunities, best practices, entry strategies, benchmarking strategies, market positioning, product positioning, and competitive positioning.

Key questions answered

1. Which are the high-growth segments and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
2. What are market estimates and forecasts; which markets are doing well and which are not?
3. Where are the gaps and opportunities; what factors are driving market growth?
4. Which are the key playing fields and winning-edge imperatives?
5. What is the competitive landscape; who are the main players in each segment; what are their strategic directives, operational strengths, key selling products, and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies.

TABLE OF CONTENTS

1 INTRODUCTION
  1.1 Key take-aways
  1.2 Report description
  1.3 Markets covered
  1.4 Stakeholders

2 SUMMARY

3 MARKET OVERVIEW
  3.1 Evolution of autoimmune treatment
  3.2 Development of autoimmune treatment market
  3.3 Defining the autoimmune treatment market
  3.4 The autoimmune treatment market by geography

4 GLOBAL AUTOIMMUNE TREATMENT MARKET BY APPLICATIONS
  4.1 Systemic autoimmune diseases
  4.2 Rheumatoid arthritis (RA)
      4.2.1 Drivers
      4.2.1.1 Large number of ra patients
     4.2.1.2 RA requires continuous treatment as it as a chronic disease
      4.2.1.3 Middle-aged population more prone to RA
      4.2.2 Restraints
     4.2.2.1 No standard treatment is available for RA
     4.2.2.2 Low insurance coverage and reimbursement for RA
      4.2.3 Global RA market for consultation & diagnosis
      4.2.4 Global RA market for therapy & monitoring
     4.2.4.1 Global RA DMARD and biologic DMARD therapy market
     4.2.4.2 Global RA bridge therapy market
     4.2.4.3 Global other RA therapies market
      4.2.5 Global RA drugs market
     4.2.5.1 Global RA NSAID market
     4.2.5.2 Global RA corticosteroids market
     4.2.5.3 Global other RA drugs market
      4.2.6 Global other RA products and services market
      4.2.7 Competitive analysis
      4.2.8 Drug approvals
  4.3 Psoriasis
      4.3.1 Drivers
     4.3.1.1 Large patient base
     4.3.1.2 Psoriasis is a chronic, genetically-transferred disease
      4.3.2 Straints
     4.3.2.1 No defined diagnosis or treatment
     4.3.2.2 OTC drugs can produce adverse drug reactions
      4.3.3 Global psoriasis consultation & diagnosis market
      4.3.4 Global psoriasis therapy & monitoring market
      4.3.5 Global psoriasis drugs
     4.3.5.1 Global anthralin psoriasis market
     4.3.5.2 Global calcipotriene psoriasis market
     4.3.5.3 Global NSAIDS psoriasis market
      4.3.6 Competitive Analysis
  4.4 Lupus
  4.5 Other systemic diseases
  4.6 Localized autoimmune diseases
  4.7 Multiple sclerosis (MS)
      4.7.1 Drivers
      4.7.1.1 MS is a chronic disorder requiring lifetime treatment
     4.7.1.2 Increased public awareness induces early treatment
     4.7.1.3 Combination therapies increase growth opportunities
      4.7.2 Restraints
     4.7.2.1 Complicated disease and limited drugs
     4.7.2.2 Side-effects of injectables and high cost of oral drugs
      4.7.3 Global multiple sclerosis drugs market
      4.7.4 Competitive analysis
      4.7.5 Drug approval
  4.8 Inflammatory bowel disease (IBD)
      4.8.1 Drivers
     4.8.1.1 IBD is a genetic disease requiring lifelong treatment
     4.8.1.2 Early treatment of IBD is driving the market
      4.8.2 Restraints
     4.8.2.1 Insurance coverage reimbursement problems
      4.8.3 Global IBD consultation & diagnosis market
      4.8.4 Global IBD therapy & monitoring market
      4.8.5 Global IBD drugs market
      4.8.6 Competitive Analysis
  4.9 Type I diabetes
      4.9.1 Drivers & restraints
      4.9.2 Competitive analysis
  4.10 Drug approvals
  4.11 Thyroid disease
  4.12 Other localized autoimmune diseases

5 GLOBAL AUTOIMMUNE TREATMENT MARKET BY PRODUCT
  5.1 Drugs
      5.1.1 Non-steroidal anti-inflammatory drugs (NSAID)
     5.1.1.1 Drivers
     5.1.1.2 Restraints
      5.1.2 Glucocorticoids
      5.1.3 Methotrexate
     5.1.3.1 Drivers & restraints
      5.1.4 Hydroxychloroquine (HCQ)
     5.1.4.1 Drivers
     5.1.4.2 Restraints
      5.1.5 Anthralin
      5.1.6 Calicipotriene
      5.1.7 Corticosteriods (Steriods)
      5.1.8 Aminosalicylates/5-Asa/Mesalazine
      5.1.9 Avonex
      5.1.10 Rebif
      5.1.11 Copaxone
      5.1.11.1 Less side effects is increasing the demand
      5.1.11.2 Reduces relapses in relapsing-remitting multiple sclerosis (RRMS)
      5.1.12 Betaseron
      5.1.13 Comparison of Four MS Drugs
      5.1.14 Other Drugs
  5.2 Diagnostic equipment
  5.3 Therapeutic and monitoring equipment
  5.4 Other products

6 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT
  6.1 Consultation & diagnosis
  6.2 Therapy and monitoring
  6.3 Drug development
      6.3.1 Drivers
      6.3.1.1 Drugs generate the most revenue
     6.3.1.2 Biosimilars are creating more opportunities

7 GLOBAL TECHNOLOGY MARKET IN AUTOIMMUNE TREATMENT
  7.1 DMARD and biologic DMARD therapy
      7.1.1 Drivers
     7.1.1.1 Effective therapies with biologic DMARD & multiple drugs
     7.1.1.2 Cost-effective treatment boosting demand
      7.1.2 Restraints
  7.2 Bridge therapy
  7.3 Topical therapy
  7.4 Phototherapy
  7.5 Helminthic therapy
      7.5.1 Drivers & restraints
            7.5.1.1 Higher efficacy
     7.5.1.2 Expensive treatment
  7.6 Fecal bacteriotherapy
  7.7 Hematopoietic stem cell transplantation
      7.7.1.1 Drivers & restraints
  7.8 Recombinant technology

8 GEOGRAPHIC ANALYSIS OF AUTOIMMUNE TREATMENT MARKET
  8.1 Autoimmune treatment market in North America
      8.1.1 North American autoimmune treatment market by applications
  8.2 Autoimmune treatment market in Europe
      8.2.1 European autoimmune treatment market by applications
  8.3 Autoimmune treatment market in Asia Pacific
  8.4 Autoimmune treatment market in ROW

9 PATENT ANALYSIS
  9.1 Analysis of patents by geography

10 COMPANY PROFILES
   10.1 4SC AG
   10.2 ABBOTT LABORATORIES
   10.3 ACTIVE BIOTECH
   10.4 AMGEN
   10.5 ANGIOTECH PHARMACEUTICALS
   10.6 ASTELLAS PHARMA
   10.7 ASTRAZENECA PLC
   10.8 AUTOIMMUNE INC
   10.9 BAYER-SCHERING PHARMACEUTICALS
   10.10 BIOCRYST PHARMACEUTICALS INC.
   10.11 BIOGEN IDEC, INC.
   10.12 BOEHRINGER INGELHEIM GMBH
   10.13 BRISTOL-MYERS SQUIBB CO.
   10.14 CENTOCOR, INC
   10.15 CYTOKINE PHARMASCIENCES, INC
   10.16 ELAN CORPORATION, PLC
   10.17 ELI LILLY & CO.
   10.18 FOREST LABORATORIES, INC.
   10.19 GALDERMA LABORATORIES
   10.20 GENENTECH, INC.
   10.21 GLAXO SMITHKLINE PLC
   10.22 ISIS PHARMACEUTICALS, INC.
   10.23 ISOTECHNIKA, INC.
   10.24 JOHNSON & JOHNSON
   10.25 LIGAND PHARMACEUTICALS
   10.26 LUPIN
   10.27 MERK SERONO SA
   10.28 MITSUBISHI TANABE PHARMA CORP
   10.29 NOVARTIS
   10.30 PFIZER
   10.31 ROCHE
   10.32 SANOFI-AVENTIS
   10.33 SCHERING-PLOUGH
   10.34 TEVA
   10.35 UCB PHARMA INC
   10.36 VERTEX PHARMACEUTICALS INC
   10.37 WARNER CHILCOTT
   10.38 WATSON PHARMACEUTICALS, INC
   10.39 WYETH
   10.40 ZYMOGENETICS, INC.

APPENDIX 
U.S. Patent 
EUROPE Patent 
JAPAN Patent

LIST OF TABLES 

Summary Table Global Market For Autoimmune Treatment, By Applications 2007 – 2014 ($Millions) 
 
1 Global autoimmune treatment market 2007 – 2014 ($Millions)
2 Global systemic diseases market, by applications 2007 – 2014 ($Millions)
3 Global systemic diseases market, by geography 2007 – 2014 ($Millions)
4 Global rheumatoid arthritis market, by applications 2007 – 2014 ($Millions)
5 Global rheumatoid arthrits applications market, by geography 2007 – 2014 ($Millions)
6 Global RA consultation & diagnosis market by geography 2007 – 2014 ($Millions)
7 Global RA therapy and monitoring market by technology 2007 – 2014 ($Millions)
8 Global RA therapy and monitoring market, by geography 2007 – 2014 ($Millions)
9 Global RA DMARD and biologic DMARD therapy market, by geography 2007 – 2014 ($Millions)
10 Global RA bridge therapy market, by geography 2007 – 2014 ($Millions)
11 Global other RA therapies market, by geography 2007 – 2014 ($Millions)
12 Global RA drugs market, by products 2007 – 2014 ($Millions)
13 Global RA drugs market, by geography 2007 – 2014 ($Millions)
14 Global RA NSAID market, by geography 2007 – 2014 ($Millions)
15 Global RA corticosteriods market, by geography 2007 – 2014 ($Millions)
16 Global other RA drugs market, by geography 2007 – 2014 ($Millions)
17 Global other RA products and services market, by geography 2007 – 2014 ($Millions)
18 Major companies and their RA products
19 Mergers and acquisitions in the RA market
20 Global psoriasis market, by products 2007 – 2014 ($Millions)
21 Global psoriasis applications market, by geography 2007 – 2014 ($Millions)
22 Global psoriasis consultation & diagnosis market, by geography 2007 – 2014 ($Millions)
23 Global psoriasis therapy & monitoring market, by technology 2007 – 2014 ($Millions)
24 Global psoriasis therapy and monitoring market, by geography 2007 – 2014 ($Millions)
25 Global psoriasis drugs market, by products 2007 – 2014 ($Millions)
26 Global psoriasis drugs market, by geography 2007 – 2014 ($Millions)
27 Global anthralin psoriasis market, by geography 2007 – 2014 ($Millions)
28 Global calcipotriene psoriasis market by geography 2007 – 2014 ($Millions)
29 Global NSAID psoriasis market, by geography 2007 – 2014 ($Millions)
30 Major companies and their psoriasis products
31 Mergers & acquisitions in the psoriasis market
32 Global lupus market, by applications 2007 – 2014 ($Millions)
33 Global lupus market, by geography 2007 – 2014 ($Millions)
34 Global other systemic autoimmune diseases market, by applications 2007 – 2014 ($Millions)
35 Global other systemic autoimmune diseases market, by geography 2007 – 2014 ($Millions)
36 Global localized diseases market, by applications 2007 – 2014 ($ Millions)
37 Global localized diseases market, by geography 2007 – 2014 ($Millions)
38 Global multiple sclerosis applications market 2007 – 2014 ($Millions)
39 Global multiple sclerosis applications market, by geography 2007 – 2014 ($Millions)
40 Global MS drugs market, by products 2007 – 2014 ($Millions)
41 Major companies and their MS products
42 Mergers & acquisitions in the MS market
43 Global inflammatory bowel disease market, by applications 2007 – 2014 ($Millions)
44 Global inflammatory bowel disease market by geography 2007 – 2014 ($Millions)
45 Global IBD consultation & diagnosis market, by geography 2007 – 2014 ($Millions)
46 Global IBD therapy & monitoring market, 2007 – 2014 ($Millions)
47 Global IBD drugs market, by products 2007 – 2014 ($Millions)
48 Global IBD drugs market, by geography 2007 – 2014 ($Millions)
49 Major companies and their IBD products
50 Mergers and acquisitions in IBD market
51 Global type I diabetes market, by applications 2007 – 2014 ($Millions)
52 Global type I diabetes market, by geography 2007 – 2014 ($Millions)
53 Major companies and their type I diabetes products
54 Mergers and acquisitions in the type I diabetes market
55 Global thyroid market, by applications 2007 – 2014 ($Millions)
56 Global thyroid market, by geography 2007 – 2014 ($Millions)
57 Global other localized autoimmune diseases market, by applications 2007 – 2014 ($Millions)
58 Global other localized autoimmune diseases market, by geography 2007 – 2014 ($Millions)
59 Global autoimmune treatment market, by products 2007 – 2014 ($Millions)
60 Global autoimmune treatment products market, by geography 2007 – 2014 ($Millions)
61 Global autoimmune drugs market, by products 2007 – 2014 ($Millions)
62 Global autoimmune drugs market, by geography 2007 – 2014 ($Millions)
63 Global NSAID market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
64 Global glucocorticoids market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
65 Global methorexate market in autoimmune treatment,by geography 2007 – 2014 ($Millions)
66 Global HCQ market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
67 Global HCQ market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
68 Global calcipotriene market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
69 Global corticosteriods market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
70 Global aminosalicylates/5-Asa/Mesalazine market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
71 Global avonex market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
72 Lobal rebif market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
73 Global copaxone market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
74 Global betaseron market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
75 Global other autoimmune drugs market, by geography 2007 – 2014 ($Millions)
76 Global autoimmune diagnostic equipment market, by products 2007 – 2014 ($Millions)
77 Global autoimmune diagnostic equipment market, by geography 2007 – 2014 ($Millions)
78 Global autoimmune therapeutic and monitoring equipment market, by geography 2007 – 2014 ($Millions)
79 Global other autoimmune products market, by geography 2007 – 2014 ($Millions)
80 Global services market in autoimmune treatment 2007 – 2014 ($Millions)
81 Global services market in autoimmune treatment, by geography 2007 – 2014 ($Millions)
82 Global autoimmune consultation & diagnosis market by geography 2007 – 2014 ($Millions)
83 Global autoimmune therapy & monitoring market by geography 2007 – 2014 ($Millions)
84 Global autoimmune drug development market by geography 2007 – 2014 ($Millions)
85 Global autoimmune treatment technology market, by products 2007 – 2014 ($Millions)
86 Global autoimmune treatment technology market, by geography 2007 – 2014 ($Millions)
87 Global DMARD and biologic DMARD technology market, by geography 2007 – 2014 ($Millions)
88 Global autoimmune bridge therapy market, by geography 2007 – 2014 ($Millions)
89 Global autoimmune topical therapy market, by geography 2007 – 2014 ($Millions)
90 Global autoimmune phototherapy market, by geography 2007 – 2014 ($Millions)
91 Global autoimmune helminthic therapy market, by geography 2007 – 2014 ($Millions)
92 Global autoimmune hematopoietic stem cell transplantation market, by geography 2007 – 2014 ($Millions)
93 Global autoimmune recombinant technology market, by geography 2007 – 2014 ($Millions)
94 Global autoimmune treatment market, by geography 2007 – 2014 ($Millions)
95 North American autoimmune treatment market, by applications 2007 – 2014 ($Millions)
96 European autoimmune treatment market, by applications 2007 – 2014 ($Millions)
97 Asia Pacific autoimmune treatment market, by applications 2007 – 2014 ($ Millions)
98 ROW autoimmune treatment market, by applications 2007 – 2014 ($Millions)

LIST OF FIGURES 
 
1 Factors causing autoimmune diseases
2 Chronology of evolution of therapies and drugs
3 Focus levels for growth in autoimmune treatment
4 Global autoimmune market, by geography for 2009
5 Classification of autoimmune diseases by applications
6 Positioning applications in the market for autoimmune treatment
7 Market share of autoimmune drugs in 2009
8 Comparison of four major drugs in MS applications
9 European markets for autoimmune treatment, in 2009 (%)
10 Number of patents issued (January 2004 – June 2009)
11 Number of patents issued by geography (January 2004 – June 2009)
12 Geographical analysis (January 2004 – June 2009)

Autoimmune Treatment Market

Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.

The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.

The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.

The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.

The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.

Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.

North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014

This Report Covers Following Niche Markets : Autoimmune Treatment Market, Pharmaceutical Industry Analysis, Drug Development Market, Clinical Diagnostic Market, Autoimmune Market Research, Autoimmune Market Report, Autoimmune Market Size, Autoimmune Treatment Market Trends